Key facts
- This page summarizes John Neis's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Dec 2025, 18:00.
John Neis - 12 Dec 2025 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)
- Reporting relationship
- Director
- Issuer ticker
- CLRB
- Reported as of
- 12 Dec 2025
- Net transaction value
- -$732
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2025, 18:00:11 UTC
- Prior SEC filing
- 18 Feb 2025
- Next SEC filing
- 08 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christina Blakley, attorney-in-fact for John Neis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Neis filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 16 Dec 2025.
Change
- Previous filing in this sequence was filed on 18 Feb 2025.
- Current net transaction value: -$732.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001167426
Primary reporting owner
NEIS JOHN
- Relationship
- Director
- Address
- C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
- Signature
- /s/ Christina Blakley, attorney-in-fact for John Neis
- Signature date
- 16 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLRB
transaction
Common Stock
Sale
- Transaction value
- $732
- Shares
- -198
- Change %
- -95%
- Price
- $3.70
- Shares after
- 10
- Date
- 12 Dec 2025
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.631 to $3.70, inclusive. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote (1) to this Form 4.
Footnote F2
This number has been adjusted for (i) the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025, (ii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022, and (iii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 16, 2018.
Footnote F3
These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.